目的:探讨复方丹参注射液对早发型重度子痫前期患者及新生儿的疗效。方法:选取2013年3月—2015年3月于宝鸡市妇幼保健院产科住院患者中符合早发型重度子痫前期诊断标准的患者130例,按照随机数字表法分为丹参组(67例)和对照组(63例)。对...目的:探讨复方丹参注射液对早发型重度子痫前期患者及新生儿的疗效。方法:选取2013年3月—2015年3月于宝鸡市妇幼保健院产科住院患者中符合早发型重度子痫前期诊断标准的患者130例,按照随机数字表法分为丹参组(67例)和对照组(63例)。对照组患者给予解痉、镇静、降压和适当利尿、地塞米松促进胎肺成熟、高蛋白低脂饮食等常规治疗,丹参组患者在对照组治疗的基础上接受复方丹参注射液治疗,2组患者均治疗2周。治疗结束后比较2组患者血清一氧化氮(NO)、内皮素1(ET-1)、肿瘤坏死因子α(TNF-α)、白细胞介素6(IL-6)变化的差异;比较2组患者治疗前、后血压以及娩出新生儿孕周、产后新生儿死亡数、胎盘质量、存活新生儿体质量、1 min Apgar评分等指标的差异。结果:2组患者治疗前各项指标比较差异均无统计学意义(P>0.05);2组患者治疗后血清ET-1、ET-1/NO、TNF-α和IL-6水平以及收缩压、舒张压和平均动脉压均较治疗前降低,NO水平显著升高(P<0.05)。丹参组治疗前后ET-1、ET-1/NO、TNF-α、IL-6的下降程度和NO的升高程度高于对照组(P<0.001)。丹参治疗组新生儿病死率低于对照组,在分娩活胎的研究对象中,丹参组患者治疗后分娩孕周长于对照组(P<0.001),胎盘质量、存活新生儿体质量、胎盘质量和存活新生儿1 min Apgar评分均高于对照组(P<0.001)。结论:复方丹参注射液可通过调节内皮细胞功能、发挥抗炎作用而降低早发型重度子痫前期患者血压,且能显著改善娩出新生儿的预后。展开更多
To systematically evaluate the clinical effectiveness and safety of Danshen Injection ( DS) as one adjuvant treatment for conventional therapy with Western medicine (WM) for unstable angina pectoris (UAP). Using liter...To systematically evaluate the clinical effectiveness and safety of Danshen Injection ( DS) as one adjuvant treatment for conventional therapy with Western medicine (WM) for unstable angina pectoris (UAP). Using literature databases, a thorough and systematic retrieval of randomized controlled trials (RCTs) comparing DS plus WM with WM was conducted from inception to April 2015. The extracted data from included studies was analyzed by Review Manager 5.2 software. The Cochrane risk of bias tool was used to assess the quality of included studies, and Begg's and Egger's tests conducted by Stata 12.0 were used to evaluate the potential presence of publication bias. A total of 17 RCTs, which involving 1,433 participants, were identified and reviewed. The meta-analysis indicated that the combined use of DS and WM was significantly superior to WM alone for UAP in terms of the total effectiveness rate of angina pectoris [risk ratio (RR) =1.23, 95% confidence interval (CI): 1.17, 1.29, P < 0.01] and the total effectiveness rate of electrocardiogram (ECG) [RR=1.18, 95%CI: 1.06, 1.30, P=0.001]. Additionally, DS could also further reduce the content of fibrinogen, adjust blood lipid level, correct T wave inversion, and so on. Fifteen adverse drug reactions were reported in two studies, Four of which appeared in the experimental group. Based on the systematic review, the combined use of DS and WM was more effective than WM alone, it can be further widely used in clinic, however, there was no exact conclusion for its safety.展开更多
文摘目的:探讨复方丹参注射液对早发型重度子痫前期患者及新生儿的疗效。方法:选取2013年3月—2015年3月于宝鸡市妇幼保健院产科住院患者中符合早发型重度子痫前期诊断标准的患者130例,按照随机数字表法分为丹参组(67例)和对照组(63例)。对照组患者给予解痉、镇静、降压和适当利尿、地塞米松促进胎肺成熟、高蛋白低脂饮食等常规治疗,丹参组患者在对照组治疗的基础上接受复方丹参注射液治疗,2组患者均治疗2周。治疗结束后比较2组患者血清一氧化氮(NO)、内皮素1(ET-1)、肿瘤坏死因子α(TNF-α)、白细胞介素6(IL-6)变化的差异;比较2组患者治疗前、后血压以及娩出新生儿孕周、产后新生儿死亡数、胎盘质量、存活新生儿体质量、1 min Apgar评分等指标的差异。结果:2组患者治疗前各项指标比较差异均无统计学意义(P>0.05);2组患者治疗后血清ET-1、ET-1/NO、TNF-α和IL-6水平以及收缩压、舒张压和平均动脉压均较治疗前降低,NO水平显著升高(P<0.05)。丹参组治疗前后ET-1、ET-1/NO、TNF-α、IL-6的下降程度和NO的升高程度高于对照组(P<0.001)。丹参治疗组新生儿病死率低于对照组,在分娩活胎的研究对象中,丹参组患者治疗后分娩孕周长于对照组(P<0.001),胎盘质量、存活新生儿体质量、胎盘质量和存活新生儿1 min Apgar评分均高于对照组(P<0.001)。结论:复方丹参注射液可通过调节内皮细胞功能、发挥抗炎作用而降低早发型重度子痫前期患者血压,且能显著改善娩出新生儿的预后。
基金Supported by the National Natural Science Foundation of China(No.81473547)Scientific Research Innovation Team Project of Beijing University of Chinese Medicine,China(No.2011-CXTD-14)
文摘To systematically evaluate the clinical effectiveness and safety of Danshen Injection ( DS) as one adjuvant treatment for conventional therapy with Western medicine (WM) for unstable angina pectoris (UAP). Using literature databases, a thorough and systematic retrieval of randomized controlled trials (RCTs) comparing DS plus WM with WM was conducted from inception to April 2015. The extracted data from included studies was analyzed by Review Manager 5.2 software. The Cochrane risk of bias tool was used to assess the quality of included studies, and Begg's and Egger's tests conducted by Stata 12.0 were used to evaluate the potential presence of publication bias. A total of 17 RCTs, which involving 1,433 participants, were identified and reviewed. The meta-analysis indicated that the combined use of DS and WM was significantly superior to WM alone for UAP in terms of the total effectiveness rate of angina pectoris [risk ratio (RR) =1.23, 95% confidence interval (CI): 1.17, 1.29, P < 0.01] and the total effectiveness rate of electrocardiogram (ECG) [RR=1.18, 95%CI: 1.06, 1.30, P=0.001]. Additionally, DS could also further reduce the content of fibrinogen, adjust blood lipid level, correct T wave inversion, and so on. Fifteen adverse drug reactions were reported in two studies, Four of which appeared in the experimental group. Based on the systematic review, the combined use of DS and WM was more effective than WM alone, it can be further widely used in clinic, however, there was no exact conclusion for its safety.
